Autoimmune Encephalitis clinical trials at UCSF
1 research study open to eligible people
Autoimmune encephalitis is a condition where the immune system targets the brain by mistake. At UCSF, research on Satralizumab is underway to observe its impact on certain encephalitis types. This involves checking how the medicine behaves inside the body and its safety.
Showing trials for
(PK), and Pharmacodynamics (PD) of Satralizumab in Participants With Anti-N-methyl-D-aspartic Acid Receptor (NMDAR) or Anti-leucine-rich Glioma-inactivated 1 (LGI1) Encephalitis
open to eligible people ages 12 years and up
The purpose of this study is to assess the efficacy, safety, PK, and PD of satralizumab in participants with NMDAR and LGI1 encephalitis.
San Francisco, California and other locations
Our lead scientists for Autoimmune Encephalitis research studies include Jeffrey Gelfand.
Last updated: